CRISPR/Cas9 Eye Drop Treatment for HSV-1 Reduces Brain Viral Load
Author Information
Author(s): Rafaela Moraes Pereira de Sousa, Luiza Silveira Garcia, Felipe Simões Lemos, Viviane Souza de Campos, Erik Machado Ferreira, Nathália Alves Araujo de Almeida, Tatiana Maron-Gutierrez, Elen Mello de Souza, Vanessa Salete de Paula
Primary Institution: Instituto Oswaldo Cruz/FIOCRUZ, Rio de Janeiro, Brazil
Hypothesis
Can CRISPR/Cas9 targeting the UL39 region reduce HSV-1 viral load in the CNS when administered via eye drops?
Conclusion
CRISPR/Cas9 therapy significantly reduced HSV-1 viral load in the brains of infected mice without causing neuronal damage.
Supporting Evidence
- CRISPR/Cas9 treatment reduced the HSV-1 viral load in the CNS of treated mice.
- Histopathological analysis showed no neuronal damage in CRISPR/Cas9 treated mice.
- Statistical significance was observed in the reduction of viral load compared to untreated controls.
Takeaway
Researchers used a special treatment called CRISPR/Cas9 in eye drops to help mice with a virus that can hurt their brains, and it worked well!
Methodology
The study involved BALB/c mice infected with HSV-1, treated with CRISPR/Cas9 via eye drops, and compared to untreated and acyclovir-treated groups.
Limitations
The study had a small sample size and a short evaluation period, limiting insights into long-term effects and latency.
Participant Demographics
Five- to six-week-old male BALB/c mice, weighing between 20 and 25 g.
Statistical Information
P-Value
p = 0.04
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website